Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;28(4):182–186. doi: 10.1002/clc.4960280405

Peripheral levels of matrix metalloproteinase‐9, interleukin‐6, and C‐reactive protein are elevated in patients with acute coronary syndromes: Correlations with serum troponin I

Athanassios Manginas 1,, Evgenia Bei 1, Antigoni Chaidaroglou 1, Dimitrios Degiannis 1, Katerina Koniavitou 1, Vassilis Voudris 1, Gregory Pavlides 1, Demosthenis Panagiotakos 1,2, Dennis V Cokkinos 1
PMCID: PMC6654195  PMID: 15869050

Abstract

Background: Acute coronary syndromes (ACS) are characterized by activation of systemic and local inflammatory mediators. The interrelation between these soluble inflammatory markers and their association with markers of myocardial necrosis have not been extensively studied.

Hypothesis: The study was undertaken to evaluate the association of the systemic levels of matrix metalloproteinase‐9 (MMP‐9) and the tissue inhibitor of metalloproteinase‐1 (TIMP‐1), with C‐reactive protein (CRP), interleukin‐6 (IL‐6), and serum troponin‐I in patients admitted with ACS.

Methods: Analysis of serum concentrations of the above inflammatory markers was performed in 53 patients with unstable angina (UA) and in 15 with non‐ST‐segment elevation myocardial infarction (NSTEMI) within 48 h of admission, and 34 patients with stable coronary artery disease.

Results: Compared with patients with stable angina, those with ACS had elevated admission levels of MMP‐9 (p = 0.04), CRP (p< 0.001), and IL‐6 (p = 0.001), but not TIMP‐1 (p = 0.55). Compared with patients with UA, those with NSTEMI also had higher levels of IL‐6 (p< 0.001), CRP (p = 0.002), and MMP‐9 (p = 0.05).

Conclusions: In patients with ACS, the admission levels of inflammatory mediators, including MMP‐9, CRP, and IL‐6 are significantly elevated, specifically in association with serum troponin I. Systemic and local markers of inflammatory activity may be directly associated with myocardial injury.

Keywords: matrix metalloproteinase‐9, acute coronary syndrome, troponin, inflammation

Full Text

The Full Text of this article is available as a PDF (35.1 KB).

References

  • 1. Dolley CM, McEvan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863–868 [DOI] [PubMed] [Google Scholar]
  • 2. Shapiro SD: Matrix metalloproteinase degradation of extracellular matrix: Biological consequences. Curr Opin Cell Biol 1998; 10: 602–608 [DOI] [PubMed] [Google Scholar]
  • 3. Shah PK, Falk E, Badimon JJ, Fernandez‐Ortiz A, Mailhac A, Villareal‐Levy G, Fallon JT, Rengstrom J, Fuster V: Human monocyte‐derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Circulation 1995; 92: 1565–1569 [PubMed] [Google Scholar]
  • 4. Li YY, McTieman CF, Feldman AM: Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 2000; 46: 214–224 [DOI] [PubMed] [Google Scholar]
  • 5. Haft JI, Mariano DL, Goldstein J: Comparison of the histopathology of culprit lesions in chronic stable angina, unstable angina, and myocardial infarction. Clin Cardiol 1997; 20: 651–655 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Braunwald E, Antman EM, Beasley JW, Calliff RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE, Steward DE, Théroux P, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC: ACC/AHA 2002 guidelines update for the management of patients with unstable angina and non‐ST segment elevation myocardial infarction. A report of the ACC/AHA Task Force on practice guidelines (Committee on the management of patients with unstable angina). J Am Coll Cardiol 2002; 40 Available at: http://www.acc.org [DOI] [PubMed] [Google Scholar]
  • 7. Braunwald E: Unstable angina: A classification. Circulation 1989; 80: 410–414 [DOI] [PubMed] [Google Scholar]
  • 8. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuahara F, Ueno T, Sugi K, Imaizzumi T: Peripheral blood levels of matrix metalloproteases‐2 and ‐9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368–372 [DOI] [PubMed] [Google Scholar]
  • 9. Inocubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K: Plasma levels of matrix metalloproteinase‐9 and tissue inhibitor of metalloproteinase‐1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141: 211–217 [DOI] [PubMed] [Google Scholar]
  • 10. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT: Macrophage infiltration in acute coronary syndromes. Circulation 1994; 90: 775–778 [DOI] [PubMed] [Google Scholar]
  • 11. Tziakas DN, Chalikias GK, Parissis JT, Hatzinikolaou EI, Papadopoulos ED, Tripsiannis GA, Papadopoulou EG, Tentes IK, Karas SM, Chatseras DI: Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short‐term atorvastatin administration. Int J Cardiol 2004; 94: 269–277 [DOI] [PubMed] [Google Scholar]
  • 12. Nomoto K, Ogushi S, Watanabe I, Kushiro T, Kanmatsutse K: Involvement of inflammation in acute coronary syndromes assessed by levels of high‐sensitivity C‐reactive protein, matrix metalloproteinase‐9 and soluble vascular‐cell adhesion molecule‐1. J Cardiol 2003; 42: 201–206 [PubMed] [Google Scholar]
  • 13. Moukarbel GV, Arnaout MS, Alam SE: C‐reactive protein is a marker for a complex culprit lesion anatomy in unstable angina. Clin Cardiol 2001; 24: 506–510 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Rajavashist TB, Xu XP, Jovinge S, Meisel S, Xu XO, Chai NN, Fishbein MC, Kaul S, Cercek B, Sharifi B, Shah PK: Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: Evidence for activation by proinflammatory cytokines. Circulation 1999; 99: 3103–3109 [DOI] [PubMed] [Google Scholar]
  • 15. Saren P, Welgus HG, Kovanen PT: TNF‐a and IL‐1b selectively induce expression of 92‐kDa gelatinase by human macrophages. J Immunol 1996; 157: 4159–4165 [PubMed] [Google Scholar]
  • 16. Biasucci LM, Vitelli A, Liuzzo G, Altamura S, Caligiuri G, Moanco C, Rebuzzi AG, Ciliberto G, Maseri A: Elevated levels of interleukin‐6 in unstable angina. Circulation 1996; 94: 874–877 [DOI] [PubMed] [Google Scholar]
  • 17. Rader DJ: Inflammatory markers of coronary risk. N Engl J Med 2000; 343: 1179–1182 [DOI] [PubMed] [Google Scholar]
  • 18. Cusack MR, Marber MS, Lambiase PD, Bucknall CA, Redwood SR: Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol 2002; 39: 1917–1923 [DOI] [PubMed] [Google Scholar]
  • 19. Mazzone A, De Servi S, Mazzucchelli I, Bossi I, Vezzoli M, Meloni F, Lotzinker M, Mariani G: Increased concentrations of inflammatory mediators in unstable angina: Correlation with serum troponin T. Heart 2001; 85: 571–575 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES